» Articles » PMID: 35611399

Predictors of All-cause Mortality Among Patients Hospitalized with Influenza, Respiratory Syncytial Virus, or SARS-CoV-2

Overview
Publisher Wiley
Specialty Microbiology
Date 2022 May 25
PMID 35611399
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Shared and divergent predictors of clinical severity across respiratory viruses may support clinical and community responses in the context of a novel respiratory pathogen.

Methods: We conducted a retrospective cohort study to identify predictors of 30-day all-cause mortality following hospitalization with influenza (N = 45,749; 2010-09 to 2019-05), respiratory syncytial virus (RSV; N = 24 345; 2010-09 to 2019-04), or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; N = 8988; 2020-03 to 2020-12; pre-vaccine) using population-based health administrative data from Ontario, Canada. Multivariable modified Poisson regression was used to assess associations between potential predictors and mortality. We compared the direction, magnitude, and confidence intervals of risk ratios to identify shared and divergent predictors of mortality.

Results: A total of 3186 (7.0%), 697 (2.9%), and 1880 (20.9%) patients died within 30 days of hospital admission with influenza, RSV, and SARS-CoV-2, respectively. Shared predictors of increased mortality included older age, male sex, residence in a long-term care home, and chronic kidney disease. Positive associations between age and mortality were largest for patients with SARS-CoV-2. Few comorbidities were associated with mortality among patients with SARS-CoV-2 as compared with those with influenza or RSV.

Conclusions: Our findings may help identify patients at greatest risk of illness secondary to a respiratory virus, anticipate hospital resource needs, and prioritize local prevention and therapeutic strategies to communities with higher prevalence of risk factors.

Citing Articles

Differences in clinical characteristics between coronavirus disease 2019 (COVID-19) and influenza: a systematic review and meta-analysis.

Han Y, Guo J, Li X, Zhong Z NPJ Prim Care Respir Med. 2025; 35(1):8.

PMID: 39875405 PMC: 11775258. DOI: 10.1038/s41533-025-00414-0.


Burden of disease of respiratory syncytial virus in older adults and adults considered at high risk of severe infection.

Abrams E, Doyon-Plourde P, Davis P, Lee L, Rahal A, Brousseau N Can Commun Dis Rep. 2025; 51(1):26-34.

PMID: 39781233 PMC: 11709116. DOI: 10.14745/ccdr.v51i01a04.


A Narrative Review of Key Risk Factors for Severe Illness Following SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus Infection.

Branche A, Ramesh M, Francis B Infect Dis Ther. 2024; 14(Suppl 1):39-61.

PMID: 39739198 PMC: 11724830. DOI: 10.1007/s40121-024-01081-3.


Summary of the National Advisory Committee on Immunization (NACI) Supplemental Guidance on Influenza Vaccination in Adults 65 Years of Age and Older.

Doyon-Plourde P, Sinilaite A, Papenburg J Can Commun Dis Rep. 2024; 50(11):387-392.

PMID: 39525077 PMC: 11542547. DOI: 10.14745/ccdr.v50i11a02.


Characteristics and outcomes of patients hospitalized for infection with Influenza A, SARS-CoV-2 or respiratory syncytial virus in the season 2023/2024 in a large German primary care centre.

Wiechert L, Fischer C, Jorres R, Engelhardt S, Alter P, Kahnert K Eur J Med Res. 2024; 29(1):509.

PMID: 39439011 PMC: 11495040. DOI: 10.1186/s40001-024-02096-9.


References
1.
Piroth L, Cottenet J, Mariet A, Bonniaud P, Blot M, Tubert-Bitter P . Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2020; 9(3):251-259. PMC: 7832247. DOI: 10.1016/S2213-2600(20)30527-0. View

2.
Ackerson B, Tseng H, Sy L, Solano Z, Slezak J, Luo Y . Severe Morbidity and Mortality Associated With Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults. Clin Infect Dis. 2018; 69(2):197-203. PMC: 6603263. DOI: 10.1093/cid/ciy991. View

3.
Childs A, Zullo A, Joyce N, McConeghy K, van Aalst R, Moyo P . The burden of respiratory infections among older adults in long-term care: a systematic review. BMC Geriatr. 2019; 19(1):210. PMC: 6683564. DOI: 10.1186/s12877-019-1236-6. View

4.
Jansen A, Sanders E, Hoes A, van Loon A, Hak E . Influenza- and respiratory syncytial virus-associated mortality and hospitalisations. Eur Respir J. 2007; 30(6):1158-66. DOI: 10.1183/09031936.00034407. View

5.
Chung H, Buchan S, Campigotto A, Campitelli M, Crowcroft N, Dubey V . Influenza Vaccine Effectiveness Against All-Cause Mortality Following Laboratory-Confirmed Influenza in Older Adults, 2010-2011 to 2015-2016 Seasons in Ontario, Canada. Clin Infect Dis. 2020; 73(5):e1191-e1199. PMC: 8423473. DOI: 10.1093/cid/ciaa1862. View